APOE-Targeted Therapeutics for Alzheimer's Disease

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Apolipoprotein E (APOE) is the primary brain lipid transporter, vital for neuronal and vascular health.
• The APOE ε4 allele (APOE4) impairs lipid transport and receptor binding, disrupting homeostasis.
• APOE4 is a significant genetic risk factor for Alzheimer's disease (AD).

Purpose of the Study:

• To review the interconnected effects of APOE4 on AD pathogenesis.
• To explore emerging therapeutic strategies targeting APOE4-related mechanisms.
• To explain the limited success of current AD therapies in APOE4 carriers.

Main Methods:

• Literature review of APOE biology and its role in AD.
• Analysis of APOE4's impact on lipid handling, neuroinflammation, and neuronal function.
• Categorization of APOE4's effects into three key pathological "hits".

Main Results:

• APOE4 disrupts brain lipid handling, leading to neuroinflammation and blood-brain barrier breakdown.
• These disruptions contribute to neuronal dysfunction and increased AD vulnerability.
• Current AD therapies targeting amyloid and tau show limited efficacy in APOE4 carriers.

Conclusions:

• APOE4-driven pathology involves interconnected disruptions in lipid handling, neuroinflammation, and neuronal function.
• Targeting these specific APOE4 mechanisms offers potential for novel AD therapies.
• APOE-focused strategies could complement existing treatments and improve outcomes for at-risk individuals.